We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Rapid Method Detects Urinary Tract Infections

By LabMedica International staff writers
Posted on 22 May 2012
The reliability of a rapid detection method for urinary tract infection (UTI) has been compared with the reference standard streaked agar plate method. More...


The novel CultureStat Rapid UTI Detection System (CSRUDS) consists of a vacuum-sealed glass ampoule containing trypticase soy broth dry media and triphenyl tetrazolium chloride, a chromophore indicator sensitive to dehydrogenase.

Scientists at Columbia University Medical Center, (New York, NY, USA) working with others, selected 980 clean catch urine samples into specimen cups during a 30-day period. Each specimen was streaked on separate 5% sheep blood agar plates and simultaneously a 7-mL aliquot of each fresh urine specimen was processed using the CSRUDS. A spectrophotometer linked to a computer and a bar code scanner was used to identify and test each urine sample.

Positive UTI conditions were accurately identified by both CSRUDS and agar streak plate methods. CSRUDS accurately identified UTI negative conditions with 99.3% reliability at 90 minutes. The negative predictive value of CSRUDS was 99.2% at 30 minutes. The bacterial plating results revealed that 413 (58.8%) of the CSRUDS negative group demonstrated no bacterial growth at all, and 289 (41.2%) of the CSRUDS negative group showed some degree of bacterial growth. Of the 289 samples, 82 (28.4%, including one of the six CSRUDS false-negative samples), showed bacterial growth in the 50,000 colony forming units (CFU) range and 200/289 (69.2%), including the other five false-negative CSRUDS samples, had CFU counts of 1,000-49,000 CFUs or mixed flora. Of the 289, 7 (2.4%) had growth greater than 100,000 colonies/mL.

The author concluded that he novel rapid detection system evaluated in this test program, the CSRUDS and MB80CSENC spectrophotometer (MicroBionetics, Eldersburg, MD, USA) provided UTI negative/positive same-day results within 90 minutes from the start of the test, with a highly reliable negative predictive value within 30 minutes for most patients. Because it is such a rapid test, contamination at urine collection is unlikely to affect the results of the assay. Specimen transport and delays in processing the urine sample are obviated because the test can be immediately performed in the urologist's office where the specimen was collected. The study was published in the April 2012 issue of the journal Urology.

Related Links:
Columbia University Medical Center
MicroBionetics


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
POC Immunoassay Analyzer
Procise DX
Thyroid Test
Anti-Thyroid EIA Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Pathology

view channel
image Credit: iStock

Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer

Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.